Apr. 10 at 7:51 AM
$AARD 1/3
A biotech stock that came to my attention is AARD. Here my thoughts:
First, the negative aspects:
- The company has an ATM that allows it to sell up to
$150 million worth of shares.
- The pipeline focuses on a single lead compound, namely ARD-101. As for ARD-101, a Phase 3 trial was voluntarily halted in late February because reversible QRS prolongations were observed at therapeutic doses above the target levels during routine safety monitoring in a study with healthy volunteers.
The result: Stock price plummeted from
$12 to under
$4 now. But without this drop, I wouldn’t even consider the stock in the first place.
